Dexmedetomidine in delirium at the end of life

Phase 1

Completed

• Conditions: Delirium at the end of life; Neurological - Other neurological disorders

• Registration Number: ACTRN12618000658213
• Lead Sponsor: Illawarra Shoalhaven Local Health District

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2018-04-24
• Study Completion: 2020-05-27
• Last Update Posted: 15 June 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 22

Inclusion Criteria

Admitted to the Port Kembla Palliative Care Unit at Illawarra Shoalhaven Local Health District
English Speaking
Develop a terminal delirium during admission
End of life

Exclusion Criteria

Non English speaking
Severe left ventricular dysfunction of <20% EF
Severe renal failure of eGFR of 30 or less
Severe hepatic failure with MELD score of 30 or greater
Bradycardia with restring heart rate of <65 BPM on screening

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change in delirium measured on Memorial Delirium Assessment Scale (MDAS), with NuDESC informing metric[Up to 10 days post initiation of dexmedetomidine infusion Assessments will be performed every 8 hours (once per nursing shift for NuDESC and daily for MDAS)<br>]

Secondary Outcome Measures

Name	Time	Method
Change in sedation measured on RASS score[Up to 10 days post initiation of dexmedetomidine infusion<br>Assessments will be performed every 8 hours (once per nursing shift).]